A team of international scientists has made a groundbreaking discovery that could pave the way for an effective treatment for amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease ...

Gnome Sciences, a molecular pathology and translational research services company, announced a significant advance in the fight against ALS (amyotrophic lateral sclerosis). In a newly published study, ...

Researchers at Tel Aviv University led a large-scale international study that opens a new avenue for treating the fatal ...

Testing showed that Gonzalez’ ALS was caused by a mutation in the SOD1 gene (Super Oxide Dismutase 1), which meant she was ...

Spinogenix received FDA authorization earlier this year for an Expanded Access Program, providing access to 200 ALS individuals ineligible for clinical trials in the United States. SPG302 has also ...

SPG302 was well tolerated in a trial, with preliminary data supporting the idea the therapy might slow ALS progression.

Preclinical data showed imaging agent ACI-19626 can selectively bind to abnormal clumps of the TDP-43 protein, a hallmark of ALS.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved RELYVRIO™ ...

Evidence is emerging that amyotrophic lateral sclerosis (ALS) may have an autoimmune component — a finding that, if confirmed, could shape the development of new therapies and prognostic tools.

She told Newsweek: “The results of this study indicate that whether we look as U.S. data from the CDC, or global data from ...